Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
Completed · Phase 2 · Has a placebo group
Conditions studied: Chronic Hepatitis B
In brief
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod in participants with chronic hepatitis B (CHB) infection currently being treated with oral antivirals (OAV). Participants will be randomized in 3 sequential cohorts (Cohorts A, B, and C). Within each cohort, participants will be randomized in a 1:3:3:3 ratio to placebo or one of the doses of vesatolimod (1, 2, or 4 mg).
Key facts
- Study ID
- NCT02166047
- Run by
- Gilead Sciences
- People needed
- 162
- Starts
- 2014-06-30
- Expected to finish
- 2016-10-20
- Last updated by the study team
- 2020-10-14
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Los Angeles, California, United States
- Study site — San Diego, California, United States
- Study site — San Francisco, California, United States
- Study site — San Jose, California, United States
- Study site — Honolulu, Hawaii, United States
- Study site — Boston, Massachusetts, United States
- Study site — Boston, Massachusetts, United States
- Study site — Detroit, Michigan, United States
- Study site — Flushing, New York, United States
- Study site — Vancouver, British Columbia, Canada
- Study site — Winnipeg, Manitoba, Canada
- Study site — Toronto, Ontario, Canada
- Study site — Toronto, Ontario, Canada
- Study site — San Giovanni Rotondo, FG, Italy
- Study site — Milan, Italy
- Study site — Parma, Italy
- Study site — Pisa, Italy
- Study site — Rotterdam, Netherlands
- Study site — Auckland, New Zealand
- Study site — Seoul, South Korea
- Study site — Seoul, South Korea
- Study site — Seoul, South Korea
- Study site — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.